Condition: Non-Small Cell Lung Cancer · KRAS G12C Lung Cancer · Sponsor: Hoffmann-La Roche
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC).
This description comes directly from the study's public registry record.
Reference Study ID Number: CO45042 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 (U.S. and Canada) · global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Always discuss trial participation with your own doctor first.
| Alaska Oncology and Hematology | Anchorage, Alaska, United States | Recruiting |
| City of Hope - Phoenix | Goodyear, Arizona, United States | Recruiting |
| Marin Cancer Care Inc | Greenbrae, California, United States | Recruiting |
| Hoag Memorial Hospital | Newport Beach, California, United States | Recruiting |
| Palo Alto Medical Foundation Research Center | Palo Alto, California, United States | Recruiting |
| Sutter Institute for Medical Research | Roseville, California, United States | Recruiting |
| California Pacific Medical Center | San Francisco, California, United States | Recruiting |
| UC Health Oncology Research | Colorado Springs, Colorado, United States | Recruiting |
| Poudre Valley Health Care, Inc. d/b/a Poudre Valley Health System | Fort Collins, Colorado, United States | Recruiting |
| Hartford Hospital | Hartford, Connecticut, United States | Recruiting |
| Florida Cancer Specialists - SOUTH - SCRI - PPDS | Fort Myers, Florida, United States | Recruiting |
| University of Florida Health at Shands | Gainesville, Florida, United States | Recruiting |
+ 248 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06793215